GlassScriptPhysician profile
Moustafa A Youssef
NPI 1477745537
$16,371.43
in general payments reported to CMS, 2019-2025
47 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,369 · 2020: $573 · 2021: $1,065 · 2022: $1,048 · 2023: $1,748 · 2024: $3,213 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,169 · Travel and Lodging: $1,131 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,169.20 |
| Travel and Lodging | $1,130.91 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $6,445.51 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $2,183.21 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Genentech USA, INC. | $1,681.49 | 2024 | |
| Endogastric Solutions, INC | $1,346.52 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $712.42 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $623.92 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $442.87 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $367.36 | 2022-2025 | Dupixent |
| Genzyme Corporation | $268.23 | 2022-2025 | |
| Pfizer INC. | $232.61 | 2022-2025 | |
| Qol Medical, LLC | $216.48 | 2022-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $182.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $175.08 | 2021-2024 | Dificid |
| Braintree Laboratories, INC. | $172.03 | 2019-2025 | Suflave |
| Intercept Pharmaceuticals, INC. | $152.62 | 2020-2025 | Ocaliva |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $138.43 | 2022-2025 | Omvoh |
| Ethicon US, LLC | $112.41 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $100.80 | 2020-2024 | Linzess |
| Janssen Scientific Affairs, LLC | $92.59 | 2023 | Tremfya, Stelara, Remicade |
| Ardelyx, INC. | $88.15 | 2023-2025 | Ibsrela |
| Covidien LP | $84.46 | 2020 | |
| Celltrion USA INC. | $72.05 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $59.57 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $53.26 | 2023 | Injectafer |
| Lumendi LLC | $51.61 | 2019 | |
| Fresenius Kabi USA, LLC | $34.70 | 2023 | Idacio |
| Nestle Healthcare Nutrition INC. | $31.61 | 2020-2023 | |
| Gilead Sciences, INC. | $30.26 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $28.87 | 2021-2022 | |
| Redhill Biopharma INC. | $27.33 | 2023 | Talicia |
| Alfasigma USA, INC. | $23.78 | 2020 | |
| Alexion Pharmaceuticals, INC. | $23.12 | 2019 | |
| Novo Nordisk INC | $22.91 | 2025 | Wegovy |
| Shionogi INC | $19.24 | 2019 | |
| Aimmune Therapeutics, INC. | $17.03 | 2025 | Zenpep |
| Vivus LLC | $16.83 | 2025 | Pancreaze |
| Pharmacosmos Therapeutics INC. | $14.16 | 2020 | |
| Medtronic, INC. | $13.59 | 2021 | |
| Allergan, INC. | $11.40 | 2020 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$28,330.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moustafa Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.